Salary Range:CHF169,400.00 - CHF314,600.00 Job Description SummaryJoin us in a high-impact leadership role at the forefront of Oncology drug development. As Senior Global Program Safety Team Lead, you will bring clinical insight, strategic thinking, and strong leadership
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Job Description Summary #LI-HybridInternal job title: DirectorLocation: Basel, Switzerland Translational Medicine Discovery & Profiling (TMDP) is a group of physicians and clinical researchers who drive innovative science from discovery to the patient through the selection, profiling,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Summary Internal job title: Director Location: Basel, Switzerland About The Role Translational Medicine Discovery & Profiling (TMDP) is a group of physicians and clinical researchers who drive innovative science from discovery to the patient through the
The Institute of Molecular and Clinical Ophthalmology Basel (IOB) is seeking an experienced and highly motivated Research Associate to join the Mitochondrial Biology and Therapy Group led by Dr. Temurkhan Ayupov. IOB combines basic and clinical
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)